Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00006093 · ClinicalTrials.gov registry record · Phase 1

EMD 121974 in Treating Patients With Progressive or Recurrent Glioma

A Phase 1 study of Brain and Central Nervous System Tumors, sponsored by New Approaches to Brain Tumor Therapy Consortium.

Completed
Registry status
Phase 1
Development phase
10
Study locations

NCT00006093 is a Phase 1 study of Brain and Central Nervous System Tumors that has completed, run by New Approaches to Brain Tumor Therapy Consortium. The trial reports 10 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00006093, a Phase 1 study of Brain and Central Nervous System Tumors, has completed, sponsored by New Approaches to Brain Tumor Therapy Consortium.

COMPLETED
Registry status
Phase 1
Development phase
10
Study locations

Study Summary

RATIONALE: EMD 121974 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of EMD 121974 in treating patients who have progressive or recurrent malignant glioma.

Conditions Studied

Brain and Central Nervous System Tumors

Interventions

  • DRUG cilengitide

Study Locations (10)

Alabama

  • University of Alabama at Birmingham Comprehensive Cancer Center - Birmingham

Florida

  • H. Lee Moffitt Cancer Center and Research Institute - Tampa

Georgia

  • Emory University Hospital - Atlanta - Atlanta

Maryland

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore

Massachusetts

  • Massachusetts General Hospital Cancer Center - Boston

Michigan

  • Henry Ford Hospital - Detroit

North Carolina

  • Comprehensive Cancer Center at Wake Forest University - Winston-Salem

Ohio

  • Cleveland Clinic Taussig Cancer Center - Cleveland

Trial Details

FieldValue
Start Date 2000-09
Est. Completion 2006-10
Phase Phase 1

Sponsor

New Approaches to Brain Tumor Therapy Consortium

10 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00006093

The ClinicalTrials.gov registry entry for NCT00006093 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is New Approaches to Brain Tumor Therapy Consortium, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 1 intervention - of which cilengitide is the first listed.

NCT00006093 reports 10 study locations spanning 10 distinct geographic areas - top geographies include Alabama, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT00006093 about?

NCT00006093 is a clinical study titled "EMD 121974 in Treating Patients With Progressive or Recurrent Glioma". RATIONALE: EMD 121974 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of EMD 121974 in treating patients who have progressive or recurrent malignant glioma.

What is the current status of trial NCT00006093?

This trial is currently completed. It is a Phase 1 study. The study started on 2000-09. Estimated completion is 2006-10.

What conditions does trial NCT00006093 study?

This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.

What interventions are being tested in trial NCT00006093?

The interventions under investigation include: cilengitide (DRUG).

Who is sponsoring clinical trial NCT00006093?

This trial is sponsored by New Approaches to Brain Tumor Therapy Consortium, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00006093 being conducted?

This trial has 10 study locations across Alabama, Florida, Georgia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Brain and Central Nervous System Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Brain and Central Nervous System Tumors

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.